Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
3.250
-0.020 (-0.61%)
At close: Jul 10, 2026, 4:00 PM EDT
3.207
-0.043 (-1.34%)
After-hours: Jul 10, 2026, 8:00 PM EDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$81,000
Profits / Employee
-$1,965,600
Market Cap
7.14M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| Bolt Biotherapeutics | 23 |
| XTL Biopharmaceuticals | 10 |
| CNS Pharmaceuticals | 8 |
| Ernexa Therapeutics | 7 |
| Kairos Pharma | 4 |
| Acurx Pharmaceuticals | 4 |
| Addex Therapeutics | 3 |
CANF News
- 6 days ago - Can-Fite BioPharma (CANF) Completes Patient Enrollment for Psoriasis Study - GuruFocus
- 6 days ago - Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial - TheFly
- 6 days ago - Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 - GlobeNewsWire
- 10 days ago - CANF Reiterated by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus
- 10 days ago - Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright - TheFly
- 11 days ago - Can-Fite BioPharma (CANF) Reports Positive Results in Namodenoson Study - GuruFocus
- 11 days ago - Can-Fite's Namodenoson Shows Survival Benefits In Pancreatic Cancer; Stock Jumps Pre-Market - Nasdaq
- 11 days ago - Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint - TheFly